Denosumab combined with immunotherapy,radiotherapy,and granulocyte-macrophage colony-stimulating factor for the treatment of metastatic nasopharyngeal carcinoma:A case report  

作　　者：Wei-Wu Chen Yue-Hong Kong Li-Yuan Zhang 

机构地区：[1]Center for Cancer Diagnosis and Treatment,The Second Affiliated Hospital of Soochow University,Suzhou 215000,Jiangsu Province,China

出　　处：《World Journal of Clinical Oncology》2025年第2期130-143,共14页世界临床肿瘤学杂志（英文）

基　　金：Supported by The Suzhou Medical Center,No.Szlcyxzx202103;The National Natural Science Foundation of China,No.82171828;The Key R and D Plan of Jiangsu Province(Development of Social),No.BE2021652;The Subject Construction Support Project of The Second Affiliated Hospital of Soochow University,No.XKTJHRC20210011;The Wu Jieping Medical Foundation,No.320.6750.2021-01-12;The Special Project of"Technological Innovation"Project of CNNC Medical Industry Co.Ltd,No.ZHYLTD2021001;The Suzhou Science and Education Health Project,No.KJXW2021018;Foundation of Chinese Society of Clinical Oncology,No.Y-pierrefabre202102-0113 and No.Y-XD202002/zb-0015;The Beijing Bethune Charitable Foundation,No.STLKY0016;The Research Projects of China Baoyuan Investment Co.Ltd,No.270004;The Suzhou Gusu Health Talent Program,No.GSWS2022028;The Open Project of State Key Laboratory of Radiation Medicine and Protection of Soochow University,No.GZN1202302;The New Medical Technology Project of the Second Affiliated Hospital of Soochow University,No.23zl001;The Multi-center Clinical Research Project for Major Diseases in Suzhou,No.DZXYJ202304;The Postgraduate Research and Practice Innovation Program of Jiangsu Province,No.SJCX24_1814;The Gusu Health Talent Research Fund,No.GSWS2022053;The National Natural Science Foundation of China,No.82102824;The Scientific Research Program for Young Talents of China National Nuclear Corporation。

摘　　要：BACKGROUND Bone is a major site of metastasis in nasopharyngeal carcinoma(NPC).Recently,nuclear factor kappa-beta ligand(RANKL)inhibitors have garnered attention for their ability to inhibit osteoclast formation and bone resorption,as well as their potential to modulate immune functions and thereby enhance the efficacy of programmed cell death protein 1(PD-1)inhibitor therapy.CASE SUMMARY We present a case of a patient with NPC who developed sternal stalk metastasis and multiple bone metastases with soft tissue invasion following radical chemoradiotherapy and targeted therapy.Prior to chemotherapy,the patient experienced severe bone marrow suppression and opted out of further chemotherapy sessions.However,the patient received combination therapy,including RANKL inhibitors(denosumab)alongside PD-1,radiotherapy,and granulocyte-macrophage colonystimulating factor(PRaG)therapy(NCT05435768),and achieved 16 months of progression-free survival and more than 35 months of overall survival,without encountering any grade 2 or higher treatment-related adverse events.CONCLUSION Denosumab combined with PRaG therapy could be a new therapeutic approach for the second-line treatment in patients with bone metastases.

关 键 词：Nasopharyngeal carcinoma Bone metastasis RADIOTHERAPY Programmed cell death protein 1 inhibitors DENOSUMAB Case report 

分 类 号：R739.6[医药卫生—肿瘤]